Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 76420-107

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 76420-107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 2: Mean Daytime Heartburn Scores Rab-usa-2 (Rabeprazole Fig2)

A line chart depicting mean heartburn scores over a study period of 42 days, including 14 days before and 28 days after day 0. The chart compares three groups: placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg, showing heartburn severity scores ranging from 0 (none) to 4 (very severe).*

FDA Label Image

Figure 3: Mean Nighttime Heartburn Scores Rab-usa-2 (Rabeprazole Fig3)

A line graph showing mean heartburn scores over a study period of 28 days, comparing placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg groups. The x-axis represents study days, while the y-axis displays mean heartburn scores from 0 (none) to 4 (very severe). The graph includes sample sizes for each group and depicts trends in symptom severity over time.*

FDA Label Image

Figure 4: Mean Daytime Heartburn Scores Rab-usa-3 (Rabeprazole Fig4)

A line graph depicting mean heartburn scores over 28 study days for two groups: placebo (n=58) and Rabeprazole Sodium 20 mg (n=59). The x-axis represents study days, and the y-axis shows mean score severity from 0 (none) to 4 (very severe). The Rabeprazole group shows a greater reduction in heartburn scores compared to placebo after day 0.*

FDA Label Image

Figure 5: Mean Nighttime Heartburn Scores Rab-usa-3 (Rabeprazole Fig5)

A line graph comparing mean heartburn scores over a 28-day study period for two groups: placebo (n=58) and Rabeprazole Sodium 20 mg (n=59). The x-axis shows study days from -14 to 28, and the y-axis indicates the mean heartburn score from 0 (none) to 4 (very severe). The graph displays a decline in heartburn scores after day 0 for both groups, with the Rabeprazole Sodium group showing a consistently lower mean score than the placebo group throughout the study.*

FDA Label Image

Package Label.principal Display Panel (Rabeprazole Fig6)

Packaging labels for Rabeprazole Sodium DR Tablets 20 mg by Enovachem Pharmaceuticals. Three labels show different package quantities: 30 tablets (NDC 76420-107-30), 90 tablets (NDC 76420-107-90), and 60 tablets (NDC 76420-107-60). Labels include distributor and relabeler information, storage instructions, drug status as prescription, and QR codes.*

FDA Label Image

Chemical Structure (Rabeprazole Str)

Chemical structure of rabeprazole sodium, showing the arrangement of atoms including nitrogen, sulfur, oxygen, sodium, and aromatic rings consistent with the molecular composition of rabeprazole sodium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.